Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Total Liabilities (2023 - 2025)

Beta Bionics (BBNX) has disclosed Total Liabilities for 3 consecutive years, with $41.1 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 44.14% to $41.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.1 million through Dec 2025, down 44.14% year-over-year, with the annual reading at $41.1 million for FY2025, 44.14% down from the prior year.
  • Total Liabilities hit $41.1 million in Q4 2025 for Beta Bionics, up from $35.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $228.8 million in Q3 2024 to a low of $24.3 million in Q1 2025.
  • Historically, Total Liabilities has averaged $102.1 million across 3 years, with a median of $51.4 million in 2023.
  • Biggest five-year swings in Total Liabilities: skyrocketed 43.16% in 2024 and later crashed 88.68% in 2025.
  • Year by year, Total Liabilities stood at $51.4 million in 2023, then surged by 43.16% to $73.6 million in 2024, then crashed by 44.14% to $41.1 million in 2025.
  • Business Quant data shows Total Liabilities for BBNX at $41.1 million in Q4 2025, $35.3 million in Q3 2025, and $28.3 million in Q2 2025.